Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 7/2017

28.02.2017 | Original Article – Clinical Oncology

The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy

verfasst von: Jingjing Miao, Weiwei Xiao, Lin Wang, Fei Han, Haijun Wu, Xiaowu Deng, Xiang Guo, Chong Zhao

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to investigate the significance of the Prognostic Nutritional Index (PNI) in predicting prognoses and guiding treatment choices of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT).

Methods

The 539 patients with newly diagnosed non-metastatic NPC were retrospectively analysed. The PNI was calculated as 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). All patients were split randomly into a training set and a testing set. Receiver operating characteristic (ROC) curves were used to identify the cut-off value of PNI and test its prognostic validity. Survival curves were calculated by Kaplan–Meier method, and differences were compared with log-rank test.

Results

The median follow-up time was 109.5 months. The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) of the whole cohort were 90.6, 85.8, 85.3 and 82.7%, respectively. The PNI cut-off value was 52.0 in the training set, which was significant in predicting DMFS, DSS and OS in the testing set. According to the PNI cut-off value, 220 patients of II–IVb stage treated by concurrent chemoradiotherapy (CCRT) were classified into PNI ≤ 52.0 and >52.0 groups and the 5-year LRRFS, DMFS, DSS, and OS of PNI ≤ 52.0 group were significantly worse than the PNI > 52.0 group.

Conclusion

Our results suggest that the PNI is a reliable independent prognostic factor in NPC patients treated with IMRT. For stage II-IVb patients with PNI ≤ 52.0, CCRT alone does not achieve satisfactory outcomes, and further studies on treatment optimization are needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Capuano G, Grosso A, Gentile PC, Battista M, Bianciardi F, Di Palma A, Pavese I, Satta F, Tosti M, Palladino A, Coiro G, Di Palma M (2008) Influence of weight loss on outcomes in patients with head and neck cancer undergoing concurrent chemoradiotherapy. Head Neck 30(4):503–508. doi:10.1002/hed.20737 CrossRefPubMed Capuano G, Grosso A, Gentile PC, Battista M, Bianciardi F, Di Palma A, Pavese I, Satta F, Tosti M, Palladino A, Coiro G, Di Palma M (2008) Influence of weight loss on outcomes in patients with head and neck cancer undergoing concurrent chemoradiotherapy. Head Neck 30(4):503–508. doi:10.​1002/​hed.​20737 CrossRefPubMed
Zurück zum Zitat Chen C, Fei Z, Pan J, Bai P, Chen L (2011) Significance of primary tumor volume and T-stage on prognosis in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Jpn J Clin Oncol 41:537–542. doi:10.1093/jjco/hyq242 CrossRefPubMed Chen C, Fei Z, Pan J, Bai P, Chen L (2011) Significance of primary tumor volume and T-stage on prognosis in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Jpn J Clin Oncol 41:537–542. doi:10.​1093/​jjco/​hyq242 CrossRefPubMed
Zurück zum Zitat Chen L, Mao Y-P, Xie FY, Liu LZ, Sun Y, Tian L, Tang LL, Lin AH, Li L, Ma J (2012a) The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiother Oncol 104:331–337. doi:10.1016/j.radonc.2011.10.009 CrossRefPubMed Chen L, Mao Y-P, Xie FY, Liu LZ, Sun Y, Tian L, Tang LL, Lin AH, Li L, Ma J (2012a) The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiother Oncol 104:331–337. doi:10.​1016/​j.​radonc.​2011.​10.​009 CrossRefPubMed
Zurück zum Zitat Chen L, Hu CS, Chen X-Z, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL (2012b) Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 13:163–171. doi:10.1016/S1470-2045(11)70320-5 CrossRefPubMed Chen L, Hu CS, Chen X-Z, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL (2012b) Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 13:163–171. doi:10.​1016/​S1470-2045(11)70320-5 CrossRefPubMed
Zurück zum Zitat Fleming ID, Cooper JS, Henson DE (1997) AJCC cancer staging manual. 5th edn. Lippincott-Raven, Philadelphia Fleming ID, Cooper JS, Henson DE (1997) AJCC cancer staging manual. 5th edn. Lippincott-Raven, Philadelphia
Zurück zum Zitat Guo R, Sun Y, Yu X-L, Yin WJ, Li WF, Chen YY, Mao YP, Liu LZ, Li L, Lin AH, Ma J (2012) Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol 104:294–299. doi:10.1016/j.radonc.2012.09.001 CrossRefPubMed Guo R, Sun Y, Yu X-L, Yin WJ, Li WF, Chen YY, Mao YP, Liu LZ, Li L, Lin AH, Ma J (2012) Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol 104:294–299. doi:10.​1016/​j.​radonc.​2012.​09.​001 CrossRefPubMed
Zurück zum Zitat Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, Shariat SF, Belldegrun AS, Klatte T (2015) The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. Urol Oncol 33:68.e1–68.e7. doi:10.1016/j.urolonc.2014.08.005 CrossRef Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, Shariat SF, Belldegrun AS, Klatte T (2015) The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. Urol Oncol 33:68.e1–68.e7. doi:10.​1016/​j.​urolonc.​2014.​08.​005 CrossRef
Zurück zum Zitat Hong S, Zhou T, Fang W, Xue C, Hu Z, Qin T, Tang Y, Chen Y, Ma Y, Yang Y, Hou X, Huang Y, Zhao H, Zhao Y, Zhang L (2015) The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients. Tumour Biol 36:3389–3397. doi:10.1007/s13277-014-2973-y CrossRefPubMed Hong S, Zhou T, Fang W, Xue C, Hu Z, Qin T, Tang Y, Chen Y, Ma Y, Yang Y, Hou X, Huang Y, Zhao H, Zhao Y, Zhang L (2015) The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients. Tumour Biol 36:3389–3397. doi:10.​1007/​s13277-014-2973-y CrossRefPubMed
Zurück zum Zitat Ikeya T, Shibutani M, Maeda K, Sugano K, Nagahara H, Ohtani H, Hirakawa K (2015) Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer. J Cancer Res Clin Oncol 141:307–313. doi:10.1007/s00432-014-1799-8 CrossRefPubMed Ikeya T, Shibutani M, Maeda K, Sugano K, Nagahara H, Ohtani H, Hirakawa K (2015) Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer. J Cancer Res Clin Oncol 141:307–313. doi:10.​1007/​s00432-014-1799-8 CrossRefPubMed
Zurück zum Zitat Li AC, Xiao W-W, Shen GZ, Wang L, Xu AA, Cao YQ, Huang SM, Lin CG, Han F, Deng XW, Zhao C (2015) Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy. Oncotarget 6:24511–24521. doi:10.18632/oncotarget.4312 CrossRefPubMedPubMedCentral Li AC, Xiao W-W, Shen GZ, Wang L, Xu AA, Cao YQ, Huang SM, Lin CG, Han F, Deng XW, Zhao C (2015) Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy. Oncotarget 6:24511–24521. doi:10.​18632/​oncotarget.​4312 CrossRefPubMedPubMedCentral
Zurück zum Zitat Onodera T, Goseki N, Kosaki G (1984) Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 85:1001–1005PubMed Onodera T, Goseki N, Kosaki G (1984) Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 85:1001–1005PubMed
Zurück zum Zitat Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J, Wu G (2012) A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 104:286–293. doi:10.1016/j.radonc.2012.08.013 CrossRefPubMed Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J, Wu G (2012) A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 104:286–293. doi:10.​1016/​j.​radonc.​2012.​08.​013 CrossRefPubMed
Zurück zum Zitat Ravasco P, Grillo IM, Vidal PM, Camilo ME (2005) Impact of nutrition on outcome: a prospective randomised controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27:659–668. doi:10.1002/hed.20221 CrossRefPubMed Ravasco P, Grillo IM, Vidal PM, Camilo ME (2005) Impact of nutrition on outcome: a prospective randomised controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27:659–668. doi:10.​1002/​hed.​20221 CrossRefPubMed
Zurück zum Zitat Sobin LH, Wittekind CH (2002) International Union Against Cancer (UICC): TNM classification of malignant tumors. Wiley-Liss, New York Sobin LH, Wittekind CH (2002) International Union Against Cancer (UICC): TNM classification of malignant tumors. Wiley-Liss, New York
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM Classification of Malignant Tumours, 7th edn. Wiley-Blackwell, Oxford Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM Classification of Malignant Tumours, 7th edn. Wiley-Blackwell, Oxford
Zurück zum Zitat Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ, Zhao C (2011) Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer 117:1874–1883. doi:10.1002/cncr.25754 CrossRefPubMed Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ, Zhao C (2011) Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer 117:1874–1883. doi:10.​1002/​cncr.​25754 CrossRefPubMed
Zurück zum Zitat Xiao W, Xu A, Fei Han, Lin X, Lu L, Shen G, Huang S, Fan W, Deng X, Zhao C (2015) Positron emission tomography-computed tomography before treatment is highly prognostic of distant metastasis in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy treatment: a prospective study with long-term follow-up. Oral Oncol 51:363–369. doi:10.1016/j.oraloncology.2015.01.009 CrossRefPubMed Xiao W, Xu A, Fei Han, Lin X, Lu L, Shen G, Huang S, Fan W, Deng X, Zhao C (2015) Positron emission tomography-computed tomography before treatment is highly prognostic of distant metastasis in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy treatment: a prospective study with long-term follow-up. Oral Oncol 51:363–369. doi:10.​1016/​j.​oraloncology.​2015.​01.​009 CrossRefPubMed
Zurück zum Zitat Yin J, Samawi H, Linder D (2016) Improved nonparametric estimation of the optimal diagnostic cut-off point associated with the Youden index under different sampling schemes. Biom J. doi:10.1002/bimj.201500036 PubMed Yin J, Samawi H, Linder D (2016) Improved nonparametric estimation of the optimal diagnostic cut-off point associated with the Youden index under different sampling schemes. Biom J. doi:10.​1002/​bimj.​201500036 PubMed
Zurück zum Zitat Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, You R, Hua YJ, Sun Y, Ma J, Hong MH, Chen MY (2015) Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer 51:2587–2595. doi:10.1016/j.ejca.2015.08.006 CrossRefPubMed Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, You R, Hua YJ, Sun Y, Ma J, Hong MH, Chen MY (2015) Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer 51:2587–2595. doi:10.​1016/​j.​ejca.​2015.​08.​006 CrossRefPubMed
Zurück zum Zitat Zhou GQ, Tang L-L, Mao YP, Chen L, Li WF, Sun Y, Liu LZ, Li L, Lin AH, Ma J (2012) Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys 82:e359–e365. doi:10.1016/j.ijrobp.2011.06.1967 CrossRefPubMed Zhou GQ, Tang L-L, Mao YP, Chen L, Li WF, Sun Y, Liu LZ, Li L, Lin AH, Ma J (2012) Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys 82:e359–e365. doi:10.​1016/​j.​ijrobp.​2011.​06.​1967 CrossRefPubMed
Zurück zum Zitat Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561–577PubMed Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561–577PubMed
Metadaten
Titel
The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy
verfasst von
Jingjing Miao
Weiwei Xiao
Lin Wang
Fei Han
Haijun Wu
Xiaowu Deng
Xiang Guo
Chong Zhao
Publikationsdatum
28.02.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2360-3

Weitere Artikel der Ausgabe 7/2017

Journal of Cancer Research and Clinical Oncology 7/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.